SLN · Silence Therapeutics

The thesis

Silence Therapeutics trades as a pending all-cash takeover. Merck KGaA's $20.00 per American depositary share (ADS) offer caps the upside, so the shares are more likely to lag the S&P 500 than lead it over the next three months. The case is settled by the deal steps still ahead: the proxy statement that dates the shareholder vote, sanction by the UK High Court, and German and US antitrust clearance before the targeted first-quarter 2027 completion.

The third-quarter report on 12 November 2026 kept the timetable intact. The company said the deal is still expected to close in the first quarter of 2027, and the 10-Q filed on 13 November 2026 shows $248 million of cash and short-term investments at 30 September 2026, with no debt reported. The release said the proxy statement, which will carry the scheme's explanatory statement, will be filed "if and when available". It gave no meeting dates.

The rating is Low because the shares have almost no room left to rise unless a rival bid or a raised offer appears. They closed at $19.83 on 13 November 2026, just under the cash price. That price says the market sees completion at $20.00 as likely and a competing bid as unlikely.

Bullish and bearish views on Silence Therapeutics Plc

The bull case on Silence Therapeutics Plc (SLN), in brief: a signed all-cash offer sets the value. The bear case: the offer caps the upside.

Bull case

• A signed all-cash offer sets the value. Merck KGaA agreed on 19 October 2026 to pay $20.00 per ADS in cash, an equity value of about $1.3 billion and an enterprise value of about $1.1 billion, the company announced. Finviz reported the price as a 130% premium to the 16 October 2026 close.
• The company reaffirmed the timing. The 12 November 2026 third-quarter release said the deal is still expected to close in the first quarter of 2027. The merger agreement's end date is 30 April 2027, New Moon Special Situations reported on 20 October 2026.
• The buyer's credit is confirmed. Moody's confirmed Merck KGaA's A3 long-term rating on 11 November 2026 and cited its planned acquisitions, including Silence, fiscal.ai reported. Bionity reported the purchase will be funded with new debt, and New Moon Special Situations reported the buyer's obligation carries no financing condition.
• Regulatory review is under way. The Bundeskartellamt (the German Federal Cartel Office) recorded a merger-control proceeding on 6 November 2026, fiscal.ai reported.
• The board and major holders back it. The board approved the deal unanimously, and holders of about 14% of voting power signed support agreements, according to the company's 19 October 2026 DEFA14A filing.
• Spending is falling before closing. Third-quarter research and development spending fell to $9.3 million from $20.5 million a year earlier, and the net loss narrowed to $12.4 million from $21.0 million, the company reported on 12 November 2026.

Bear case

• The offer caps the upside. The 13 November 2026 close of $19.83 sits just under the $20.00 cash price. Without a rival offer, that small gap is the only gain left before completion, which leaves the shares behind a rising index.
• A competing offer carries a cost. Silence would owe Merck KGaA a $13 million fee if it accepted a superior proposal, New Moon Special Situations reported on 20 October 2026. No competing approach had been disclosed as of the 12 November 2026 results.
• The approval steps remain undated. The scheme needs a majority in number representing at least 75% in value of holders voting at the court meeting, according to the company's filings. The 12 November 2026 release still described the proxy statement as forthcoming, with no meeting dates and no update on US antitrust review.
• The business earns nothing on its own. The 10-Q filed on 13 November 2026 shows zero revenue in the quarter to 30 September 2026 and free cash flow of minus $44 million over the four quarters to that date. Without the deal, the share price would rest on clinical data alone.
• A fairness probe is open. Halper Sadeh LLC said on 23 October 2026 it is investigating whether the $20.00 price gives shareholders fair value. A lawsuit from that probe could delay the timetable.

Price setup

The shares closed at $19.83 on 13 November 2026. The 52-week intraday high is $19.86, set on 26 October 2026; the 52-week closing low is $4.30, from 4 February 2026. Daily closes from 6 November to 13 November 2026 ranged between $19.73 and $19.83, a band of cents just under the cash price.

The three-month gain is 38.2%, measured from the 17 August 2026 close of $14.35. Almost all of it came on 19 October 2026, when the shares rose about 126% on the deal announcement, Benzinga reported.

The 50-day moving average is $14.66 and the 200-day moving average is $9.78, both as of 13 November 2026. Both sit far below the price because they still average in pre-deal trading, so they say nothing about the deal. The downside level that matters is $18.00, well under the cash price and the post-announcement range; a close there would mean the market is pricing real doubt that the deal completes. The upside is bounded by the offer unless a rival bid or a raised offer appears.

Catalysts ahead

• ~December 2026 (est.): Proxy statement with the scheme's explanatory statement for the Merck KGaA deal; the company's 12 November 2026 release gave no filing date. The filing sets the dates of the court meeting and general meeting, the first formal shareholder approval steps for the $20.00 deal, and shows whether the first-quarter 2027 timetable holds.
• 14 December 2026: Oral presentation of Phase 2 SANRECO divesiran data in polycythemia vera at the American Society of Hematology Annual Meeting. The data support the buyer's reason to close and are the most visible event that could draw a competing proposal above $20.00.
• ~March 2027 (est.): Completion of the Merck KGaA acquisition, targeted for the first quarter of 2027, after antitrust clearance, the scheme vote and UK High Court sanction. Completion pays $20.00 per ADS in cash and ends public trading in the shares; the merger agreement end date is 30 April 2027.

What would change the view

A daily close above $24.32, far over the $20.00 cash offer, which would show the market pricing a higher bid and the shares leading the S&P 500; a disclosed rival proposal or a raised Merck KGaA offer would also prove the call wrong.

What it trades with

The shares now move with the deal's odds of completing and its timetable, and very little with the S&P 500 or biotech indexes. A broad market rally does not lift a stock capped by a cash offer, which is why a rising index tends to leave it behind. Other takeover targets in the special-situations group trade on their own deal terms, so their news has little bearing here. Only deal-specific news moves the price materially: antitrust rulings, the scheme vote, the court hearing, a lawsuit or a rival bid. The 14 December 2026 presentation of Phase 2 divesiran data at the American Society of Hematology (ASH) meeting is the one clinical event in the window, and its main relevance is whether it draws a competing proposal.